Related Experiment Video
Updated: Jun 16, 2026
10:27
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
CYP2D6 testing in breast cancer: ready for prime time?
Nicole M Kuderer1, Jeffrey Peppercorn
1Division of Hematology, Oncology and Cellular Therapy, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina 27710, USA. nicole.kuderer@duke.edu
Oncology (Williston Park, N.Y.)
|February 4, 2010
Summary
Tamoxifen efficacy varies due to CYP2D6 gene variations affecting drug metabolism. Current evidence on poor metabolizer status and breast cancer recurrence is conflicting, requiring more research before routine genetic testing.
Area of Science:
- Pharmacogenomics
- Oncology
- Drug Metabolism
Background:
- Tamoxifen is a key hormonal therapy for breast cancer.
- Its efficacy relies on active metabolites like endoxifen.
- CYP2D6 genetic polymorphisms influence tamoxifen metabolism.
Purpose of the Study:
- To investigate the clinical relevance of CYP2D6 genetic variations on tamoxifen response.
- To clarify the association between CYP2D6 metabolizer status and breast cancer outcomes.
Main Methods:
- Review of retrospective studies examining CYP2D6 polymorphisms and tamoxifen efficacy.
- Analysis of endoxifen levels in patients with varying CYP2D6 activity.
Main Results:
- Conflicting findings exist regarding the association between poor CYP2D6 metabolizer status and breast cancer recurrence.
- Some studies suggest increased recurrence, while others show no association or improved outcomes.
Conclusions:
- Current evidence on CYP2D6's clinical utility in tamoxifen therapy is preliminary and conflicting.
- Further research, including analysis of large randomized trials, is needed to establish routine CYP2D6 testing as standard of care.
